Related Experiment Video
Updated: Jun 15, 2026
06:51
Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy
Published on: December 17, 2019
Building better chimeric antigen receptors for adoptive T cell therapy
John S Bridgeman1, Robert E Hawkins, Andreas A Hombach
1Cellular Therapy Group, Cancer Research UK Department of Medical Oncology, Paterson Institute for Cancer Research, Manchester, UK.
Current Gene Therapy
|March 13, 2010
Summary
Chimeric antigen receptor (CAR) design for cancer therapy is debated. This review examines CAR structures and conflicting results to guide future rational design for optimal tumor targeting.
Area of Science:
- Immunology
- Biotechnology
- Oncology
Background:
- Chimeric antigen receptors (CARs) are engineered T-cell receptors for cancer immunotherapy.
- Two decades of CAR research have led to clinical trials, yet optimal design remains debated.
- The archetypal CAR structure involves a tumor-specific antibody fragment fused to CD3zeta for T-cell activation.
Purpose of the Study:
- To provide a structural overview of CAR development.
- To highlight areas needing refinement in CAR design.
- To identify reasons for conflicting results in CAR efficacy and inspire rational design strategies.
Main Methods:
- Review of existing literature on CAR structure and function.
- Analysis of modifications to CAR components (extracellular spacer, transmembrane, cytoplasmic domains).
- Examination of factors contributing to conflicting results in CAR studies.
Main Results:
- CARs are modular, allowing structural modifications for enhanced activity.
- No consensus exists on the optimal CAR structure.
- Conflicting results are observed even with identical CAR constructs.
Conclusions:
- Further refinement of CAR structural components is necessary.
- Understanding the basis for conflicting results is crucial for future development.
- Rational design strategies are needed for optimal CAR-based tumor targeting.
